BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: McCann DJ, Petry NM, Bresell A, Isacsson E, Wilson E, Alexander RC. Medication Nonadherence, "Professional Subjects," and Apparent Placebo Responders: Overlapping Challenges for Medications Development. J Clin Psychopharmacol 2015;35:566-73. [PMID: 26244381 DOI: 10.1097/JCP.0000000000000372] [Cited by in Crossref: 37] [Cited by in F6Publishing: 19] [Article Influence: 6.2] [Reference Citation Analysis]
Number Citing Articles
1 Liu AY, Laborde ND, Coleman K, Vittinghoff E, Gonzalez R, Wilde G, Thorne AL, Ikeguchi E, Shafner L, Sunshine L, van der Straten A, Siegler AJ, Buchbinder S. DOT Diary: Developing a Novel Mobile App Using Artificial Intelligence and an Electronic Sexual Diary to Measure and Support PrEP Adherence Among Young Men Who Have Sex with Men. AIDS Behav 2021;25:1001-12. [PMID: 33044687 DOI: 10.1007/s10461-020-03054-2] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 14.0] [Reference Citation Analysis]
2 McCaul ME, Wand GS. Detecting Deception in Our Research Participants: Are Your Participants Who You Think They Are? Alcohol Clin Exp Res 2018;42:230-7. [PMID: 29286543 DOI: 10.1111/acer.13556] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
3 Czobor P, Kakuszi B, Bitter I. Placebo Response in Trials of Negative Symptoms in Schizophrenia: A Critical Reassessment of the Evidence. Schizophr Bull 2022:sbac061. [PMID: 35713342 DOI: 10.1093/schbul/sbac061] [Reference Citation Analysis]
4 Shtrichman R, Conrad S, Schimo K, Shachar R, Machluf E, Mindal E, Epstein H, Epstein S, Paz A. Use of a Digital Medication Management System for Effective Assessment and Enhancement of Patient Adherence to Therapy (ReX): Feasibility Study. JMIR Hum Factors 2018;5:e10128. [PMID: 30478020 DOI: 10.2196/10128] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
5 Serafini G, Gonda X, Canepa G, Geoffroy PA, Pompili M, Amore M. Recent Stressful Life Events in Euthymic Major Depressive Disorder Patients: Sociodemographic and Clinical Characteristics. Front Psychiatry 2020;11:566017. [PMID: 33024438 DOI: 10.3389/fpsyt.2020.566017] [Reference Citation Analysis]
6 Bain EE, Shafner L, Walling DP, Othman AA, Chuang-Stein C, Hinkle J, Hanina A. Use of a Novel Artificial Intelligence Platform on Mobile Devices to Assess Dosing Compliance in a Phase 2 Clinical Trial in Subjects With Schizophrenia. JMIR Mhealth Uhealth 2017;5:e18. [PMID: 28223265 DOI: 10.2196/mhealth.7030] [Cited by in Crossref: 43] [Cited by in F6Publishing: 33] [Article Influence: 8.6] [Reference Citation Analysis]
7 Lee CP, Holmes T, Neri E, Kushida CA. Deception in clinical trials and its impact on recruitment and adherence of study participants. Contemp Clin Trials 2018;72:146-57. [PMID: 30138717 DOI: 10.1016/j.cct.2018.08.002] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
8 Freeman MP, Pooley J, Flynn MJ, Baer L, Mischoulon D, Mou D, Fava M. Guarding the Gate: Remote Structured Assessments to Enhance Enrollment Precision in Depression Trials. J Clin Psychopharmacol 2017;37:176-81. [PMID: 28187008 DOI: 10.1097/JCP.0000000000000669] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 2.2] [Reference Citation Analysis]
9 Doran N, Dubrava S, Anthenelli RM. Effects of Varenicline, Depressive Symptoms, and Region of Enrollment on Smoking Cessation in Depressed Smokers. Nicotine Tob Res 2019;21:156-62. [PMID: 29471329 DOI: 10.1093/ntr/nty033] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
10 Brown MA, Bishnoi RJ, Dholakia S, Velligan DI. Methodological issues associated with preclinical drug development and increased placebo effects in schizophrenia clinical trials. Expert Rev Clin Pharmacol 2016;9:591-604. [PMID: 26696325 DOI: 10.1586/17512433.2016.1135734] [Reference Citation Analysis]
11 Devine EG, Peebles KR, Martini V. Strategies to exclude subjects who conceal and fabricate information when enrolling in clinical trials. Contemp Clin Trials Commun 2017;5:67-71. [PMID: 29740622 DOI: 10.1016/j.conctc.2016.12.005] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
12 Eliasson L, Clifford S, Mulick A, Jackson C, Vrijens B. How the EMERGE guideline on medication adherence can improve the quality of clinical trials. Br J Clin Pharmacol 2020;86:687-97. [PMID: 32034923 DOI: 10.1111/bcp.14240] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
13 Kirschenbaum MA, Lopez LV, de Filippis R, Ali AF, Millner AJ, Nock MK, Kane JM. Validation of a novel Psychosis-Implicit Association Test (P-IAT) as a diagnostic support tool. Psychiatry Research 2022. [DOI: 10.1016/j.psychres.2022.114647] [Reference Citation Analysis]
14 Devine EG, Pingitore AM, Margiotta KN, Hadaway NA, Reid K, Peebles K, Hyun JW. Frequency of concealment, fabrication and falsification of study data by deceptive subjects. Contemp Clin Trials Commun 2021;21:100713. [PMID: 33604482 DOI: 10.1016/j.conctc.2021.100713] [Reference Citation Analysis]
15 Tomko RL, Gray KM, Oppenheimer SR, Wahlquist AE, McClure EA. Using REDCap for ambulatory assessment: Implementation in a clinical trial for smoking cessation to augment in-person data collection. Am J Drug Alcohol Abuse 2019;45:26-41. [PMID: 29513609 DOI: 10.1080/00952990.2018.1437445] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
16 Tomko RL, McClure EA, Squeglia LM, Treloar Padovano H, McRae-Clark AL, Baker NL, Carpenter MJ, Gray KM. Methods to reduce the incidence of false negative trial results in substance use treatment research. Curr Opin Psychol 2019;30:35-41. [PMID: 30798020 DOI: 10.1016/j.copsyc.2019.01.009] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
17 Negus SS, Banks ML. Learning from lorcaserin: lessons from the negative clinical trial of lorcaserin to treat cocaine use disorder. Neuropsychopharmacology 2020;45:1967-73. [PMID: 32839526 DOI: 10.1038/s41386-020-00815-4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
18 Pavletic A, Pao M. Safety, Science, or Both? Deceptive Healthy Volunteers: Psychiatric Conditions Uncovered by Objective Methods of Screening. Psychosomatics 2017;58:657-63. [PMID: 28651795 DOI: 10.1016/j.psym.2017.05.001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
19 McNamara C, Engelhardt N, Potter W, Yavorsky C, Masotti M, Di Clemente G. Risk-Based Data Monitoring: Quality Control in Central Nervous System (CNS) Clinical Trials. Ther Innov Regul Sci 2019;53:176-82. [PMID: 29758992 DOI: 10.1177/2168479018774325] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
20 Acri JB, Cross AJ, Skolnick P. From bench to bedside: mGluR2 positive allosteric modulators as medications to treat substance use disorders. Psychopharmacology (Berl) 2017;234:1347-55. [PMID: 27995279 DOI: 10.1007/s00213-016-4501-9] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
21 Mahncke HW, Kim SJ, Rose A, Stasio C, Buckley P, Caroff S, Duncan E, Yasmin S, Jarskog LF, Lamberti JS, Nuechterlein K, Strassnig M, Velligan D, Ventura J, Walker T, Stroup TS, Keefe RSE. Evaluation of a plasticity-based cognitive training program in schizophrenia: Results from the eCaesar trial. Schizophr Res 2019;208:182-9. [PMID: 30930034 DOI: 10.1016/j.schres.2019.03.006] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
22 Dockendorf MF, Hansen BJ, Bateman KP, Moyer M, Shah JK, Shipley LA. Digitally Enabled, Patient-Centric Clinical Trials: Shifting the Drug Development Paradigm. Clin Transl Sci 2021;14:445-59. [PMID: 33048475 DOI: 10.1111/cts.12910] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
23 Mofsen AM, Rodebaugh TL, Nicol GE, Depp CA, Miller JP, Lenze EJ. When All Else Fails, Listen to the Patient: A Viewpoint on the Use of Ecological Momentary Assessment in Clinical Trials. JMIR Ment Health 2019;6:e11845. [PMID: 31066701 DOI: 10.2196/11845] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]